Ultragenyx Pharmaceutical (RARE) delivered an exceptional Q4 '18 and fiscal year 2018 results, beating the top-line analysts' estimates. Following the earnings results, the stock price surged over 6% on February 19, 2019. The management is confident about the strong business performance in 2019. It will be driven by a high probability of the successful FDA approval process of its key pipeline products as well as growing commercial activities of the already approved drugs & therapies.
President and CEO of Ultragenyx Emil D. Kakkis, M.D., Ph.D., stated:
This last year was important for Ultragenyx